The American Society of Clinical Oncology (ASCO) and The ASCO Cancer Foundation are honoring 10 community oncology practices for their efforts to improve care of people with cancer through participation in clinical trials. The Clinical Trials Participation Awards will be presented Sunday, June 1, 2008 at ASCO’s 44th Annual Meeting in Chicago. “Virtually every cancer treatment available today is the direct result of clinical research,” said ASCO President Nancy Davidson, MD.
A tiny modification called methylation on estrogen receptors prolongs the life of these growth-driving molecules in breast cancer cells, according to research by scientists at Emory University’s Winship Cancer Institute.The results are published in the May 9, 2008 issue of the journal Molecular Cell.Most breast cancers contain estrogen receptors, which enable them to grow in the presence of the hormone estrogen.
Researchers at the OU Cancer Institute have identified a new gene that causes cancer. The ground-breaking research appears Monday in Nature’s cancer journal Oncogene.The gene and its protein, both called RBM3, are vital for cell division in normal cells. In cancers, low oxygen levels in the tumors cause the amount of this protein to go up dramatically. This causes cancer cells to divide uncontrollably, leading to increased tumor formation.
Radiologists can, with confidence, recommend a six-month follow-up diagnostic mammogram rather than an immediate biopsy for patients with “probably benign” breast lesions, a new study emphasizes.The study found that six-month short-interval follow-up examinations had an 83% sensitivity, which is similar to the sensitivity of other diagnostic mammograms, said Erin J. Aiello Bowles, MPH, lead author of the study from the Group Health Center for Health Studies.
Virologist and cancer biologist Patrick Lee was on his way to the American Association of Cancer Research in San Diego last week when he decided to check out the in-flight movie I Am Legend.The premise of the sci-fi horror movie is that a virus successfully used to fight cancer in clinical trials has gone out of control, pushing humankind to the edge of extinction.
Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume, according to a study in the May issue of Plastic and Reconstructive Surgery(R), the official medical journal of the American Society of Plastic Surgeons (ASPS).
BiPar Sciences, Inc. announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on going trials in breast and brain cancer.
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced that Dana-Farber Cancer Institute has joined the University of Colorado Cancer Center in conducting a Phase 1 study of ENMD-2076 in advanced cancer patients. Dr. Geoffrey Shapiro, Dana-Farber Cancer Institute, and Dr.
Loading ...